AFR: Heidelberg Pharma AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
January 22, 2024 at 03:44 am EST
Share
EQS Preliminary announcement financial reports: Heidelberg Pharma AG
/ Preliminary announcement on the disclosure of financial statements
Heidelberg Pharma AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
22.01.2024 / 09:42 CET/CEST
Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Heidelberg Pharma AG hereby announces that the following financial reports shall be disclosed:
Report Type: Annual financial report
Language: German
Date of disclosure: March 25, 2024
Address: https://heidelberg-pharma.com/de/presse-investoren/mitteilungen-und-berichte/finanzberichte
Language: English
Date of disclosure: March 25, 2024
Address: https://heidelberg-pharma.com/en/press-investors/announcements/financial-reports
Report Type: Annual financial report of the group
Language: German
Date of disclosure: March 25, 2024
Address: https://heidelberg-pharma.com/de/presse-investoren/mitteilungen-und-berichte/finanzberichte
Language: English
Date of disclosure: March 25, 2024
Address: https://heidelberg-pharma.com/en/press-investors/announcements/financial-reports
Report Type: Financial report of the group (half-year/Q2)
Language: German
Date of disclosure: July 11, 2024
Address: https://heidelberg-pharma.com/de/presse-investoren/mitteilungen-und-berichte/finanzberichte
Language: English
Date of disclosure: July 11, 2024
Address: https://heidelberg-pharma.com/en/press-investors/announcements/financial-reports
22.01.2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com
Heidelberg Pharma AG, formerly Wilex AG, is a Germany-based Company, which is engaged in the biopharmaceuticals sector. The Company focuses on the research and development of therapy treatments for oncology area. It aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Companyâs pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. It also offers preclinical contract research services.